The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma

Elodie Vauleon; Nathalie Auger; Alexandra Benouaich-Amiel; Florence Laigle-Donadey; Gentian Kaloshi; Julie Lejeune; Jean Yves Delattre; Joëlle Thillet; Marc Sanson

doi:10.1016/j.cancergencyto.2006.07.013

The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma

Elodie Vauleon, Nathalie Auger, Alexandra Benouaich-Amiel, Florence Laigle-Donadey, Gentian Kaloshi, Julie Lejeune, Jean Yves Delattre, Joëlle Thillet, Marc Sanson

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

43 Citations (Scopus)

Résumé

The A/G61 polymorphism located in the 5′UTR of the EGF gene has been found to be both a risk factor and a prognostic factor in glioblastoma (GBM), but the functional consequences have not been investigated. Here we show, in vitro, that this polymorphism is functional, in that the G allele promoter is 40% more active than the A variant (P < 0.001). However, analysis of a large series of 209 GBM patients and 214 control subjects did not confirm that A/G61 polymorphism is a significant risk factor for GBM, despite a trend for higher GG frequency in these patients. Furthermore, A/G61 polymorphism was not a prognostic factor for survival in GBM patients, although it does appear to affect progression-free survival.

langue originale	Anglais
Pages (de - à)	33-37
Nombre de pages	5
journal	Cancer Genetics and Cytogenetics
Volume	172
Numéro de publication	1
Les DOIs	https://doi.org/10.1016/j.cancergencyto.2006.07.013
état	Publié - 1 janv. 2007

Accès au document

10.1016/j.cancergencyto.2006.07.013

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{6bb2e92f63b74ec99715a998d5bac061,

title = "The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma",

abstract = "The A/G61 polymorphism located in the 5′UTR of the EGF gene has been found to be both a risk factor and a prognostic factor in glioblastoma (GBM), but the functional consequences have not been investigated. Here we show, in vitro, that this polymorphism is functional, in that the G allele promoter is 40% more active than the A variant (P < 0.001). However, analysis of a large series of 209 GBM patients and 214 control subjects did not confirm that A/G61 polymorphism is a significant risk factor for GBM, despite a trend for higher GG frequency in these patients. Furthermore, A/G61 polymorphism was not a prognostic factor for survival in GBM patients, although it does appear to affect progression-free survival.",

author = "Elodie Vauleon and Nathalie Auger and Alexandra Benouaich-Amiel and Florence Laigle-Donadey and Gentian Kaloshi and Julie Lejeune and Delattre, {Jean Yves} and Jo{\"e}lle Thillet and Marc Sanson",

year = "2007",

month = jan,

day = "1",

doi = "10.1016/j.cancergencyto.2006.07.013",

language = "English",

volume = "172",

pages = "33--37",

journal = "Cancer Genetics and Cytogenetics",

issn = "0165-4608",

number = "1",

}

TY - JOUR

T1 - The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma

AU - Vauleon, Elodie

AU - Auger, Nathalie

AU - Benouaich-Amiel, Alexandra

AU - Laigle-Donadey, Florence

AU - Kaloshi, Gentian

AU - Lejeune, Julie

AU - Delattre, Jean Yves

AU - Thillet, Joëlle

AU - Sanson, Marc

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The A/G61 polymorphism located in the 5′UTR of the EGF gene has been found to be both a risk factor and a prognostic factor in glioblastoma (GBM), but the functional consequences have not been investigated. Here we show, in vitro, that this polymorphism is functional, in that the G allele promoter is 40% more active than the A variant (P < 0.001). However, analysis of a large series of 209 GBM patients and 214 control subjects did not confirm that A/G61 polymorphism is a significant risk factor for GBM, despite a trend for higher GG frequency in these patients. Furthermore, A/G61 polymorphism was not a prognostic factor for survival in GBM patients, although it does appear to affect progression-free survival.

AB - The A/G61 polymorphism located in the 5′UTR of the EGF gene has been found to be both a risk factor and a prognostic factor in glioblastoma (GBM), but the functional consequences have not been investigated. Here we show, in vitro, that this polymorphism is functional, in that the G allele promoter is 40% more active than the A variant (P < 0.001). However, analysis of a large series of 209 GBM patients and 214 control subjects did not confirm that A/G61 polymorphism is a significant risk factor for GBM, despite a trend for higher GG frequency in these patients. Furthermore, A/G61 polymorphism was not a prognostic factor for survival in GBM patients, although it does appear to affect progression-free survival.

UR - http://www.scopus.com/inward/record.url?scp=33845520633&partnerID=8YFLogxK

U2 - 10.1016/j.cancergencyto.2006.07.013

DO - 10.1016/j.cancergencyto.2006.07.013

M3 - Article

C2 - 17175377

AN - SCOPUS:33845520633

SN - 0165-4608

VL - 172

SP - 33

EP - 37

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

IS - 1

ER -